type
status
date
slug
summary
tags
category
icon
password
📢【新聞標題】
Ready-made stem cell therapies for pets could be coming
寵物即用型幹細胞療法即將問世
📰【摘要】
San Diego startup Gallant announced $18 million in funding to bring the first FDA-approved ready-to-use stem cell therapy to veterinary medicine. Gallant's first target is a painful mouth condition in cats called Feline Chronic Gingivostomatitis (FCGS), which Gallant says could receive FDA approval by early 2026.
聖地牙哥新創公司Gallant宣布獲得1800萬美元的資金，旨在將首個FDA批准的即用型幹細胞療法帶入獸醫學領域。Gallant的首要目標是貓咪的一種痛苦的口腔疾病，稱為貓慢性齒齦口炎（FCGS），Gallant表示該療法可能在2026年初獲得FDA批准。
🗝️【關鍵詞彙表】
📝 stem cell therapy (n.)
- 幹細胞療法
- 例句: Ready-to-use stem cell therapies for pets could be coming.
- 翻譯: 寵物即用型幹細胞療法即將問世。
📝 veterinary medicine (n.)
- 獸醫學
- 例句: Gallant announced funding to bring stem cell therapy to veterinary medicine.
- 翻譯: Gallant宣布獲得資金，旨在將幹細胞療法帶入獸醫學領域。
📝 regulatory muster (n.)
- 監管審查
- 例句: If it passes regulatory muster, it could create a whole new way to treat our fur babies.
- 翻譯: 如果它通過監管審查，它可能會創造一種全新的方式來治療我們的毛孩。
📝 Feline Chronic Gingivostomatitis (FCGS) (n.)
- 貓慢性齒齦口炎
- 例句: Gallant’s first target is a painful mouth condition in cats called Feline Chronic Gingivostomatitis (FCGS).
- 翻譯: Gallant的首要目標是貓咪的一種痛苦的口腔疾病，稱為貓慢性齒齦口炎。
📝 harvesting (v.)
- 採集
- 例句: Most stem cell treatments today require harvesting cells from the patient.
- 翻譯: 現今大多數的幹細胞治療需要從患者身上採集細胞。
📝 donor (n.)
- 捐贈者
- 例句: Gallant’s therapy uses ready-to-use cells from donor animals.
- 翻譯: Gallant的療法使用來自捐贈動物的即用型細胞。
📝 allogeneic (adj.)
- 異體的
- 例句: The evolution from autologous to allogeneic cell therapies.
- 翻譯: 從自體到異體細胞療法的演變。
✍️【文法與句型】
📝 could be coming
- 說明: Used to indicate a future possibility or likelihood.
- 翻譯: 可能會到來，即將到來
- 例句: Ready-made stem cell therapies for pets could be coming.
- 翻譯: 寵物即用型幹細胞療法即將問世。
📝 what makes... different is...
- 說明: Used to highlight the distinguishing factor or characteristic of something.
- 翻譯: ...的不同之處在於...
- 例句: What makes Gallant’s approach different is convenience.
- 翻譯: Gallant方法的不同之處在於便利性。
📖【全文與翻譯】
Earlier this week, San Diego startup Gallant announced $18 million in funding to bring the first FDA-approved ready-to-use stem cell therapy to veterinary medicine.
本週稍早，聖地牙哥新創公司Gallant宣布獲得1800萬美元的資金，旨在將首個FDA批准的即用型幹細胞療法帶入獸醫學領域。
If it passes regulatory muster, it could create a whole new way to treat our fur babies.
如果它通過監管審查，它可能會創造一種全新的方式來治療我們的毛孩。
It’s still an experimental field, even though people have been researching stem cells for humans for decades.
即使人們已經研究人類幹細胞數十年了，這仍然是一個實驗性領域。
Seven-year-old Gallant’s first target is a painful mouth condition in cats called Feline Chronic Gingivostomatitis (FCGS), which Gallant says could receive FDA approval by early 2026.
成立七年的Gallant的首要目標是貓咪的一種痛苦的口腔疾病，稱為貓慢性齒齦口炎（FCGS），Gallant表示該療法可能在2026年初獲得FDA批准。
The field has shown some encouraging early results.
該領域已經顯示出一些令人鼓舞的早期成果。
Studies on dogs with arthritis showed improvements in pain and mobility, with some benefits lasting up to two years.
對患有關節炎的狗的研究表明，疼痛和活動能力有所改善，一些益處持續長達兩年。
But when researchers tried similar treatments for kidney disease in cats — that’s another condition Gallant wants to tackle — the results were more mixed.
但是，當研究人員嘗試對貓的腎臟疾病進行類似治療時——這是Gallant想要解決的另一個問題——結果好壞參半。
What makes Gallant’s approach different is convenience.
Gallant方法的不同之處在於便利性。
Most stem cell treatments today require harvesting cells from the patient or donors with matching tissue, whereas Gallant’s therapy uses ready-to-use cells from donor animals, even if they are a different species.
現今大多數的幹細胞治療需要從患者或具有匹配組織的捐贈者身上採集細胞，而Gallant的療法使用來自捐贈動物的即用型細胞，即使它們是不同的物種。
Investors clearly see potential here.
投資者顯然看到了這裡的潛力。
The funding round was led by existing backer Digitalis Ventures, with participation from NovaQuest Capital Management, which previously invested in the first FDA-approved human stem cell therapy.
本輪融資由現有支持者Digitalis Ventures領投，NovaQuest Capital Management也參與其中，該公司之前曾投資於首個FDA批准的人類幹細胞療法。
The company has an interesting backstory.
這家公司有著有趣的背景故事。
Gallant’s founder, Aaron Hirschhorn, previously sold DogVacay to its biggest rival in the dog-sitting marketplace, Rover.
Gallant的創始人Aaron Hirschhorn之前將DogVacay出售給了其在遛狗市場上的最大競爭對手Rover。
Hirschhorn passed away in 2021; Gallant is now led by Linda Black, who joined as its president and chief scientific officer from nearly the beginning.
Hirschhorn於2021年去世；Gallant現在由Linda Black領導，她從公司創立之初就擔任總裁兼首席科學官。
Gallant has now raised at least $44 million altogether from investors.
Gallant現在已經從投資者那裡總共籌集了至少4400萬美元。
🔗【資料來源】
文章連結：<https://techcrunch.com/2025/07/04/ready-made-stem-cell-therapies-for-pets-could-be-coming/>